Payment overview · 2025
General Payments
$203.03
9 reported records · 7 companies
Healthcare provider profile · identity verified
Edward Wayne Haga, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · JACKSONVILLE, NC · NPI 1245295195
Verified facts
What the public records show
CMS Open Payments records show Edward Wayne Haga, M.D. received $203.03 in general payments during 2025 across 9 reported records.
Lundbeck LLC accounted for 22.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Rexulti, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lundbeck LLC | Unresolved — no canonical attribution shown | $45.19 | 22.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $40.83 | 20.1% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $32.94 | 16.2% | 1 | 2025 |
| PhotoniCare Inc | Unresolved — no canonical attribution shown | $28.19 | 13.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.19 | 10.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.14 | 9.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.55 | 6.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $203.03 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $45.19 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $40.83 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $32.94 | 1 | 2025 |
Source payment records
|
|||||
| OtoSight Middle Ear Scope Normalized: otosight middle ear scope |
Device | PhotoniCare Inc | $28.19 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 44 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 105 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
111 | 105 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
105 | 26 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 344 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 265 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 244 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 202 | 49 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 168 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 164 | 58 |
| Omeprazole | Omeprazole | 158 | 47 |
| Gabapentin | Gabapentin | 143 | 31 |
| Meloxicam | Meloxicam | 138 | 32 |
| Metformin Hcl Er | Metformin Hcl | 136 | 36 |
| Lisinopril | Lisinopril | 132 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 125 | 16 |
| Metformin Hcl | Metformin Hcl | 123 | 33 |
| Losartan Potassium | Losartan Potassium | 111 | 29 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 111 | 105 |
| Trazodone Hcl | Trazodone Hcl | 108 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 105 | 26 |
| Simvastatin | Simvastatin | 102 | 26 |
| Prednisone | Prednisone | 100 | 58 |
| Alendronate Sodium | Alendronate Sodium | 92 | 25 |
| Sertraline Hcl | Sertraline Hcl | 90 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 84 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 75 | suppressed |
| Furosemide | Furosemide | 73 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 72 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 26 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 65 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 61 | 23 |
| Alprazolam | Alprazolam | 57 | suppressed |
| Spironolactone | Spironolactone | 54 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 11 |
| Trulicity | Dulaglutide | 52 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 50 | suppressed |
| Ozempic | Semaglutide | 50 | 14 |
| Azithromycin | Azithromycin | 48 | 40 |
| Montelukast Sodium | Montelukast Sodium | 48 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 45 | 16 |
| Carvedilol | Carvedilol | 45 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 12 |
| Jardiance | Empagliflozin | 44 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 43 | 11 |
| Diazepam | Diazepam | 41 | suppressed |
| Nifedipine Er | Nifedipine | 41 | suppressed |
| Clonazepam | Clonazepam | 40 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 13 |
| Lorazepam | Lorazepam | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Eliquis | Apixaban | 37 | suppressed |
| Fenofibrate | Fenofibrate | 35 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | suppressed |
| Allopurinol | Allopurinol | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 14 |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Famotidine | Famotidine | 25 | suppressed |
| Potassium Chloride | Potassium Chloride | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 16 |
| Nitroglycerin | Nitroglycerin | 18 | 12 |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 15 |
| Indomethacin | Indomethacin | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Indapamide | Indapamide | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Jatenzo | Testosterone Undecanoate | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 11 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $203.03 · 9 records | Lundbeck LLC | FREESTYLE LIBRE 3, JARDIANCE, OtoSight Middle Ear Scope, REXULTI, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, WaveWriter Alpha Prime 16 | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error